Kala Bio missed the primary endpoint in the study for its treatment of Persistent Corneal Epithelial Defect, an eye defect, and said it would stop development of the drug, called KPI-012. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback